These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 6637330)
1. Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome. Laczi F; Van Ree JM; Balogh L; Szász A; Járdánházy T; Wágner A; Gáspár L; Valkusz Z; Dobranovics I; Szilárd J Acta Endocrinol (Copenh); 1983 Oct; 104(2):177-82. PubMed ID: 6637330 [TBL] [Abstract][Full Text] [Related]
2. Differential effect of desglycinamide9-(Arg8)-vasopressin on cognitive functions of diabetes insipidus and alcoholic patients. Laczi F; László FA; Kovács GL; Telegdy G; Szász A; Szilárd J; van Ree JM; de Wied D Acta Endocrinol (Copenh); 1987 Jul; 115(3):392-8. PubMed ID: 3303787 [TBL] [Abstract][Full Text] [Related]
3. Influence of desglycinamide-(arg8) vasopressin on memory in healthy subjects. Bruins J; Kumar A; Schneider-Helmert D Neuropsychobiology; 1990; 23(2):82-8. PubMed ID: 2077437 [TBL] [Abstract][Full Text] [Related]
4. Effect of acute and chronic treatment with desglycinamide-[Arg8]vasopressin in young male and female volunteers. Bruins J; Hijman R; Van Ree JM Peptides; 1995; 16(2):179-86. PubMed ID: 7784246 [TBL] [Abstract][Full Text] [Related]
5. Does DGAVP influence memory, attention and mood in young healthy men? Snel J; Taylor J; Wegman M Psychopharmacology (Berl); 1987; 92(2):224-8. PubMed ID: 3110845 [TBL] [Abstract][Full Text] [Related]
6. Effects of (DesGly9-Arg8) vasopressin on cognitive processes in alcoholic patients. Korsić M; Jokić N; Ilić-Supek D; Skocilić Z; Lovrić M; Bacić J; Jakovljević M; Maslo K; Trbović M Acta Med Iugosl; 1991; 45(3):223-9. PubMed ID: 1950641 [TBL] [Abstract][Full Text] [Related]
7. Effects of DGAVP on verbal memory. Pietrowsky R; Fehm-Wolfsdorf G; Born J; Fehm HL Peptides; 1988; 9(6):1361-6. PubMed ID: 3247253 [TBL] [Abstract][Full Text] [Related]
8. Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia. Peabody CA; Thiemann S; Pigache R; Miller TP; Berger PA; Yesavage J; Tinklenberg JR Neurobiol Aging; 1985; 6(2):95-100. PubMed ID: 3895014 [TBL] [Abstract][Full Text] [Related]
9. A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma. Bohnen NI; Twijnstra A; Jolles J Neurology; 1993 Jan; 43(1):103-6. PubMed ID: 8423870 [TBL] [Abstract][Full Text] [Related]
10. The effect of desglycinamide-(Arg8)-vasopressin (DGAVP) on the acquisition of free-choice alcohol drinking in rhesus monkeys. Kornet M; Goosen C; Ribbens LG; Van Ree JM Alcohol Clin Exp Res; 1991 Feb; 15(1):72-9. PubMed ID: 2024735 [TBL] [Abstract][Full Text] [Related]
11. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man. Jennekens-Schinkel A; Wintzen AR; Lanser JB Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(3):273-84. PubMed ID: 3898228 [TBL] [Abstract][Full Text] [Related]
12. Effect of desmopressin on normal and impaired memory. Jenkins JS; Mather HM; Coughlan AK J Neurol Neurosurg Psychiatry; 1982 Sep; 45(9):830-1. PubMed ID: 7131017 [TBL] [Abstract][Full Text] [Related]
13. Vasopressin fragment, AVP-(4-8), improves long-term and short-term memory in the hole board search task. Vawter MP; De Wied D; Van Ree JM Neuropeptides; 1997 Oct; 31(5):489-94. PubMed ID: 9413027 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. Westenberg HG; Hijman R; Wiegant VM; Laczi F; Van Ree JM Peptides; 1994; 15(6):1101-4. PubMed ID: 7991455 [TBL] [Abstract][Full Text] [Related]
15. Des-Gly9-[Arg8]-vasopressin may facilitate methadone detoxification of heroin addicts. van Beek-Verbeek G; Fraenkel HM; van Ree JM Subst Alcohol Actions Misuse; 1983; 4(5):375-82. PubMed ID: 6670060 [TBL] [Abstract][Full Text] [Related]
17. Effects of desglycinamide-arginine-vasopressin (DG-AVP) on memory processes in diabetes insipidus patients and non-diabetic subjects. Laczi F; van Ree JM; Wagner A; Valkusz Z; Járdánházy T; Kovács GL; Telegdy G; Szilárd J; László FA; de Wied D Acta Endocrinol (Copenh); 1983 Feb; 102(2):205-12. PubMed ID: 6829260 [TBL] [Abstract][Full Text] [Related]
18. Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects. Riekkinen P; Legros JJ; Sennef C; Jolkkonen J; Smitz S; Soininen H Peptides; 1987; 8(2):261-5. PubMed ID: 3588346 [TBL] [Abstract][Full Text] [Related]
19. [Functional activity of vasopressin analog desglycinamide-arginine-vasopressin]. Golubeva MG Izv Akad Nauk Ser Biol; 2006; (3):297-305. PubMed ID: 16771143 [TBL] [Abstract][Full Text] [Related]
20. Noradrenergic and cholinergic agents in Korsakoff's syndrome. O'Donnell VM; Pitts WM; Fann WE Clin Neuropharmacol; 1986; 9(1):65-70. PubMed ID: 3548954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]